Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Skye Bioscience Inc SKYE

Healthcare Biotechnology
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation... see more

Recent & Breaking News (NDAQ:SKYE)

Skye Bioscience to Present at Upcoming Investment Conferences

GlobeNewswire 2 days ago

Skye Bioscience Uplists to The Nasdaq Global Market

GlobeNewswire April 10, 2024

Skye Bioscience Announces $40 Million Private Placement Equity Financing

Newsfile March 11, 2024

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

GlobeNewswire March 4, 2024

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

GlobeNewswire February 26, 2024

Skye Bioscience to Present at Oppenheimer Investor Conference

Newsfile February 7, 2024

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Newsfile January 29, 2024

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Newsfile January 9, 2024

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

GlobeNewswire December 11, 2023

Skye Bioscience Responds to OTC Markets Promotional Policy

Newsfile December 8, 2023

Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

Newsfile December 5, 2023

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

GlobeNewswire November 28, 2023

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

Newsfile November 21, 2023

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

Newsfile October 25, 2023

CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Newsfile October 20, 2023

Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Newsfile October 19, 2023

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

Newsfile September 27, 2023

Skye Bioscience Announces Participation at Upcoming Investor Conferences

Newsfile September 22, 2023

Skye Bioscience Reverse Stock Split to Be Effective on September 8th

Newsfile September 7, 2023

Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference

Newsfile September 5, 2023